-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Lyra Therapeutics, Raises Price Target to $16

Benzinga·06/10/2025 11:12:55
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and raises the price target from $2 to $16.